Nanofacile accelerates RNA therapy development by providing advanced technology for faster and more effective formulation. Their system reduces preclinical time by a factor of ten through adaptable, high-throughput encapsulation compatible with existing wet lab workflows. This platform enables scientists to streamline the formulation process, leading to quicker results in nanomedicine development.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing RNA therapies using lipid-based nanoparticles (LNPs) is a time-consuming process, often taking weeks to optimize formulations and prove efficacy during preclinical studies. Traditional methods rely on specialized expertise and can be slow and costly, hindering the rapid development of next-generation treatments.
Solution
Nanofacile provides an advanced technology platform designed to accelerate and de-risk nanomedicine research and development. Their system enables formulation scientists and researchers to encapsulate therapeutic agents within LNPs, reducing preclinical development time from weeks to days. The platform integrates high-throughput encapsulation and optimization tools, ensuring compatibility with standard wet lab workflows. Nanofacile's technology empowers biotech innovators in both academia and the pharmaceutical industry to achieve faster, more effective results in RNA therapy development.
Target Audience
The primary customers are formulation scientists, medicinal chemists, and researchers in academia and the pharmaceutical industry involved in RNA therapy and nanomedicine development.
Features
- Adaptable throughput for encapsulating different formulations simultaneously in minutes
- Easy to integrate into existing wet lab workflows and downstream experiments
- Streamlines the process of RNA therapy development by integrating high-throughput encapsulation and optimization tools
- Facilitates rapid screening and low-volume experimentation for preclinical development